Of the 60% of adults with prediabetes at baseline, ~30% progressed to diabetes, with a median time to diabetes of 7 years (ESM Table 1)
It's worth noting that tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, representing a distinct but related medication class with similar clinical effects
Therefore, the same drug can move from covered to denied based on documentation alone
Genetic Predisposition Insights and Clinical Provider Conversations Your provider's decision to prescribe compounded semaglutide should reflect both clinical indicators and individual metabolic context
Each new discovered benefit only deepens my conviction that these medications are revolutionizing how we approach both individual and population health
Children move from phrases like marker, marker to sentences like I got a yellow marker. At this stage, the focus is on meaning, not teaching grammar